US Food and Drug Administration, Silver Spring, Maryland, USA.
Clin Pharmacol Ther. 2012 Oct;92(4):486-93. doi: 10.1038/clpt.2012.146. Epub 2012 Sep 5.
The history of medicines regulation is punctuated with sudden swings in focus mandated by a public injured by medicines and skeptical of regulators' abilities to protect them. As stakeholder communities and the science that undergirds medicines have both grown more sophisticated, seemingly conflicting mission equities, such as public health protection vs. promotion or population vs. individual patient product development focus, have created new challenges to defining the mission and role of twenty-first-century medicines regulators. The role of medicines regulators as a nationally focused, retrospective assessor of data is rapidly shifting to that of a prospective generator of public data and tools to help drive what has now become a global product development and regulatory enterprise that is fast gaining recognition as an integral part of any truly effective twenty-first-century health-care system. This article discusses this evolution and describes how regulatory science will help to both drive and define it.
药品监管的历史充满了戏剧性的转折,这些转折是由受到药品伤害且对监管机构保护他们的能力持怀疑态度的公众推动的。随着利益相关者群体和支撑药品的科学都变得更加复杂,看似相互冲突的任务权益(如公众健康保护与促进、群体与个体患者产品开发重点)给确定二十一世纪药品监管机构的使命和角色带来了新的挑战。药品监管机构作为一个专注于国家、对数据进行回顾性评估的角色,正在迅速转变为一个前瞻性的公共数据生成者和工具提供者,以帮助推动这场已经成为全球性产品开发和监管事业的发展,该事业正在迅速获得认可,成为任何真正有效的二十一世纪医疗保健系统不可或缺的一部分。本文讨论了这一演变,并描述了监管科学将如何帮助推动和定义这一演变。